Great find peaceAKKI, these kind of milestone payments are what...

Great find peaceAKKI, these kind of milestone payments are what we are looking for...


Taken from Genmab's website:

"Daratumumab has multiple mechanisms of action, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), apoptosis and modulation of CD38 enzymatic activity. In pre-clinical studies, daratumumab has been shown to effectively kill multiple myeloma cells and to enhance the potency of other multiple myeloma treatments."



Taken from PAB's news announcement:

"?It was shown conclusively that PAT-SM6 specifically targeted and bound to the myeloma cells. Furthermore analysis of patient’s immune systems indicated that PAT-SM6 is capable of inducing an immune response by both stimulating and increasing the absolute number of CD8+, NK and regulatory T-cells. These cells are specifically capable of regulating the growth and dissemination of tumours."

https://en.wikipedia.org/wiki/Regulatory_T_cell

Treg's are the holy grail of immunology...



and again from the PAB annoucement:

"Dr. Marie Roskrow, Patrys’ CEO said: “The trial results are especially exciting because they reflect single-agent activity in a difficult-to-treat population. Due to very high rates of relapse, the combination of multiple agents is increasingly becoming a therapy of choice for patients with MM."


What excites me is PAT-SM6's comparable data. A newsbyte of Genmab's phase 1/2 study results can be found here:

http://www.medpagetoday.com/HematologyOncology/Myeloma/33115


"Dose-limiting events occurred in one patient who experienced grade 3 anemia and grade 4 thrombocytopenia; one patient experienced dose-limiting liver enzyme elevations; one patients experienced grade 3 bronchospasm; and one patient experienced grade 2 cytokine release syndrome. "All patients recovered after relevant treatment," Plesner said."

And again from PAB's announcement yesterday:

"The primary endpoint of the study was safety and tolerability. At all dose levels tested, PAT-SM6 was well tolerated with no serious adverse events (SAEs) or dose limiting toxicities being reported. A maximal tolerated dose (MTD) was not reached."

Maximal tolerated dose not reached....

:)

IMHO, DYOR.